RT Generic
T1 New imaging technologies for robotic kidney cancer surgery
A1 Puliatti, Stefano
A1 Eissa, Ahmed
A1 Checcucci, Enrico
A1 Piazza, Pietro
A1 Amato, Marco
A1 Ferretti, Stefania
A1 Scarcella, Simone
A1 Rivas, Juan Gomez
A1 Taratkin, Mark
A1 Marenco, Jose
A1 Rivero, Ines Belenchon
A1 Kowalewski, Karl-Friedrich
A1 Cacciamani, Giovanni
A1 El-Sherbiny, Ahmed
A1 Zoeir, Ahmed
A1 El-Bahnasy, Abdelhamid M.
A1 De Groote, Ruben
A1 Mottrie, Alexandre
A1 Micali, Salvatore
K1 Kidney cancer
K1 Imaging
K1 Technology
K1 Robotic
K1 Assisted partial nephrectomy
K1 Indocyanine green
K1 Renal tumors
K1 Perioperative outcomes
K1 Physical models
K1 Ischemia
K1 Impact
K1 Score
K1 Reconstruction
K1 Time
AB Objective: Kidney cancers account for approximately 2% of all newly diagnosed cancer in 2020. Among the primary treatment options for kidney cancer, urologist may choose between radical or partial nephrectomy, or ablative therapies. Nowadays, robotic-assisted partial nephrectomy (RAPN) for the management of renal cancers has gained popularity, up to being considered the gold standard. However, RAPN is a challenging procedure with a steep learning curve.Methods: In this narrative review, different imaging technologies used to guide and aid RAPN are discussed.Results: Three-dimensional visualization technology has been extensively discussed in RAPN, showing its value in enhancing robotic-surgery training, patient counseling, surgical planning, and intraoperative guidance. Intraoperative imaging technologies such as intracorporeal ultrasound, near-infrared fluorescent imaging, and intraoperative pathological examination can also be used to improve the outcomes following RAPN. Finally, artificial intelligence may play a role in the field of RAPN soon.Conclusion: RAPN is a complex surgery; however, many imaging technologies may play an important role in facilitating it. (C) 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PB Elsevier singapore pte ltd
SN 2214-3882
YR 2022
FD 2022-07-01
LK http://hdl.handle.net/10668/21880
UL http://hdl.handle.net/10668/21880
LA en
DS RISalud
RD Sep 3, 2025